Trial in progress: linvoseltamab, a BCMAxCD3 bispecific antibody, in a Phase 1b multi-cohort study of combination regimens for patients with relapsed/refractory multiple myeloma

被引：0
|
作者：
Rodriguez-Otero, Paula [1 ]
Joseph, Nisha [2 ]
Kumar, Shaji [3 ]
Leleu, Xavier [4 ]
Manier, Salomon [5 ]
Dimopoulos, Meletios [6 ]
Mateos, Maria-Victoria [7 ]
Oriol, Albert [8 ,9 ]
Bumma, Naresh [10 ]
Gong, Weiying [11 ]
Roy, Pourab [11 ]
Lorenc, Karen Rodriguez [11 ]
Kroog, Glenn [11 ]
Sarkaria, Shawn [11 ]
机构：
[1] Univ Navarra Clin, CIMA, CIBERONC, IDISNA, Pamplona, Spain
[2] Emory Univ, Winship Canc Inst, Atlanta, GA USA
[3] Mayo Clin, Rochester, MN USA
[4] Hosp Mileterie, Poitiers, France
[5] Univ Lille, Ctr Hosp Univ Lille, Lille, France
[6] Natl & Kapodistrian Univ Athens, Athens, Greece
[7] Univ Hosp Salamanca, IBSAL, CIC, CIBERONC, Salamanca, Spain
[8] Catalan Inst Oncol, Hosp Germans Trias i Pujol, Badalona, Spain
[9] Josep Carreras Inst, Hosp Germans Trias i Pujol, Badalona, Spain
[10] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH USA
[11] Regeneron Pharmaceut Inc, Tarrytown, NY USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-046
引用
收藏
页码：S60 / S60
页数：1
相关论文
共 50 条
  • [21] Final Analysis of a Phase 1b Study of Daratumumab in Combination with Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma (RRMM)
    Chari, Ajai
    Lonial, Sagar
    Martinez-Lopez, Joaquin
    Mateos, Maria-Victoria
    Blade, Joan
    Benboubker, Lotfi
    Oriol, Albert
    Otero, Paula Rodriguez
    Pineiro, Luis
    Jakubowiak, Andrzej
    Olyslager, Yunsi
    Wang, Jianping
    Nnane, Ivo
    Ukropec, Jon
    Shreeve, Martin
    Qi, Ming
    Moreau, Philippe
    BLOOD, 2019, 134
  • [22] Phase 1b trial of pembrolizumab monotherapy for relapsed/ refractory multiple myeloma: KEYNOTE-013
    Ribrag, Vincent
    Avigan, David E.
    Green, Damian J.
    Wise-Draper, Trisha
    Posada, Juan G.
    Vij, Ravi
    Zhu, Ying
    Farooqui, Mohammed Z. H.
    Marinello, Patricia
    Siegel, David S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (03) : E41 - E44
  • [23] Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial
    Yee, Andrew J.
    Bensinger, William I.
    Supko, Jeff Rey G.
    Voorhees, Peter M.
    Berdeja, Jesus G.
    Richardson, Paul G.
    Libby, Edward N.
    Wallace, Ellen E.
    Birrer, Nicole E.
    Burke, Jill N.
    Tamang, David L.
    Yang, Min
    Jones, Simon S.
    Wheeler, Catherine A.
    Markelewicz, Robert J.
    Raje, Noopur S.
    LANCET ONCOLOGY, 2016, 17 (11): : 1569 - 1578
  • [24] Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study
    Biran, Noa
    Siegel, David
    Berdeja, Jesus G.
    Raje, Noopur
    Cornell, Robert Frank
    Alsina, Melissa
    Kovacsovics, Tibor
    Fang, Belle
    Kimball, Amy S.
    Landgren, Ola
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (07) : 794 - 802
  • [25] A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma
    Mikhael, Joseph
    Richardson, Paul
    Usmani, Saad Z.
    Raje, Noopur
    Bensinger, William
    Karanes, Chatchada
    Campana, Frank
    Kanagavel, Dheepak
    Dubin, Franck
    Liu, Qianying
    Semiond, Dorothee
    Anderson, Kenneth
    BLOOD, 2019, 134 (02) : 123 - 133
  • [26] A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma
    Martin, Thomas
    Baz, Rachid
    Benson, Don M.
    Lendvai, Nikoletta
    Wolf, Jeffrey
    Munster, Pamela
    Lesokhin, Alexander M.
    Wack, Claudine
    Charpentier, Eric
    Campana, Frank
    Vij, Ravi
    BLOOD, 2017, 129 (25) : 3294 - 3303
  • [27] PHASE 1B STUDY OF VENETOCLAX COMBINED WITH BORTEZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Moreau, P.
    Chanan-Khan, A.
    Roberts, A. W.
    Agarwal, A.
    Facon, T.
    Kumar, S.
    Touzeau, C.
    Diehl, S.
    Cordero, J.
    Ross, J.
    Munasinghe, W.
    Zhu, M.
    Salem, A. H.
    Leverson, J.
    Maciag, P.
    Verdugo, M.
    Harrison, S. J.
    HAEMATOLOGICA, 2016, 101 : 81 - 82
  • [28] A Phase 1b/2a Study of the CELMoD Iberdomide (CC-220) in Combination With Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
    Lonial, Sagar
    Van de Donk, Niels
    Popat, Rakesh
    Zonder, Jeffrey A.
    Minnema, Monique
    Larsen, Jeremy T.
    Tuong Vi Nguyen
    Chen, Min S.
    Bensmaine, Amine
    Peluso, Teresa
    Sonneveld, Pieter
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E52 - E53
  • [29] The TGFβ type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed/refractory multiple myeloma: a phase 1b trial
    Malek, Ehsan
    Rana, Priyanka S.
    Swamydas, Muthulekha
    Daunov, Michael
    Miyagi, Masaru
    Murphy, Elena
    Ignatz-Hoover, James J.
    Metheny, Leland
    Kim, Seong Jin
    Driscoll, James J.
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [30] Phase 1b Results for Subcutaneous Talquetamab Plus Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma
    Chari, Ajai
    Hari, Parameswaran
    Bahlis, Nizar J.
    Mateos, Maria-Victoria
    van de Donk, Niels W. C. J.
    Dholaria, Bhagirathbhai
    Garfall, Alfred L.
    Goldschmidt, Hartmut
    Kortuem, K. Martin
    Krishnan, Amrita Y.
    Martin, Thomas
    Morillo Gilles, Daniel
    Oriol, Albert
    Reece, Donna E.
    Rodriguez, Cesar
    Rodriguez-Otero, Paula
    San-Miguel, Jesus F.
    Usmani, Saad Z.
    Verona, Raluca I.
    Lin, Shun Xin Wang
    Prior, Thomas J.
    Wade, Mark
    Weiss, Brendan M.
    Goldberg, Jenna D.
    Askari, Elham
    BLOOD, 2021, 138
12345